The mission of the VRI is to conduct research to accelerate the development of effective vaccines against HIV/AIDS, HCV and emerging infectious diseases. The scientific goals of the VRI offer significant opportunities for innovation as they intend to:
- develop and extend the portfolio of candidate vaccines for HIV, HCV and emerging infectious diseases to be tested in clinical trials
- improve the technology of immunological testing for vaccine trials
- strengthen the partnership between immunologists, virologists, cell biologists, molecular biologists, primate model specialists and clinicians
- develop novel partnerships with industry
- pursue a social science program to analyze the specific issues related to communication on HIV vaccinology
- bring strong expertise on regulatory, legal and ethical aspects
- provide the optimal environment for improved coordination of an integrated scientific program and of dedicated funding
The VRI stems from the existing ANRS vaccine research program and includes research teams, core facilities, a network of clinical centers, and industry and charitable partners.
The current ongoing projects of the VRI include:
- development of vaccine candidates
- viral antigen presentation and dendritic cell (DC) biology
- immunogenicity of prime-boost strategies in non-human primate models
- study of immune correlates of protection
- phase I and II clinical trials.
With its innovative and integrated program, the VRI will develop an incentive policy for recruiting young high-potential talents, new teams and internationally recognized scientists. An attractive “starter package” will facilitate the settlement of the most promising teams within the VRI.